BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress
Abstract Title: Prophylactic Therapy with BCX7353 Reduces Anxiety and Stress in Hereditary Angioedema with C1-INH-HAE Subjects: Data from the Phase 2 APeX-1 Trial
Presenter: Dr.
Abstract Title: Analysis of Gastrointestinal Symptoms in Subjects with C1-INH deficiency HAE treated with BCX7353: Results from the Phase 2 APeX-1 Trial.
Presenter: Dr. Emel Aygören-Pürsün
Abstract Title: Pharmacokinetic and Pharmacodynamic effects of BCX7353 in Subjects with C1-INH-HAE: Results from the Phase 2 APeX-1 Trial.
Presenter: Dr.
Abstract Title: BCX7353 Improves Health-Related Quality of Life in Hereditary Angioedema with C1-inhibitor deficiency (C1-INH-HAE): Findings from the Phase 2 APeX-1 Trial
Presenter: Dr.
“These additional analyses of our Phase 2 APeX-1 trial of once-daily oral BCX7353 provide further details regarding pharmacokinetics, safety, and effects on target enzyme (plasma kallikrein) inhibition as well as measures of quality of life and symptoms of stress, anxiety and depression in patients with hereditary angioedema,” said Dr.
Copies of the posters are available on the company’s website: www.biocryst.com.
About BCX7353
Discovered by BioCryst, BCX7353 is a novel, oral, once-daily, selective inhibitor of plasma kallikrein currently in development for the prevention and treatment of angioedema attacks in patients diagnosed with HAE. BCX7353 has been generally safe and well tolerated in the Phase 2 APeX-1 clinical trial. BioCryst is currently conducting the Phase 3 APeX-2 clinical trial and the long-term safety APeX-S clinical trial, both evaluating two dosage strengths of BCX7353 administered orally once-daily as a preventive treatment to reduce the frequency of attacks in patients with HAE. BioCryst is also conducting the ZENITH-1 clinical trial. ZENITH-1 is a proof-of-concept Phase 2 clinical trial testing an oral liquid formulation of BCX7353 for the treatment of acute angioedema attacks.
About
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that developing any HAE product candidate may take longer or may be more expensive than planned; that ongoing and future preclinical and clinical development of HAE second generation drug candidates (including ZENITH-1, APeX-2 and APeX-S) may not have positive results; that BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; that the Company may not advance human clinical trials with product candidates as expected; that the FDA, EMA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, or may not provide regulatory clearances which may result in delay of planned clinical trials, or may impose a clinical hold with respect to such product candidate, or withhold market approval for product candidates. Please refer to the documents BioCryst files periodically with the
BCRXW
CONTACT:
Source: BioCryst Pharmaceuticals, Inc.